These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11583680)

  • 1. 5-S-cysteinyldopa as diagnostic tumor marker for uveal malignant melanoma.
    Goto H; Usui M; Wakamatsu K; Ito S
    Jpn J Ophthalmol; 2001; 45(5):538-42. PubMed ID: 11583680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [5-S-cysteinyldopa as a tumor marker for primary uveal malignant melanoma].
    Goto H; Tenou T; Kudo H; Iwasaki T; Muramatsu R; Usui M; Wakamatsu K; Ito S
    Nippon Ganka Gakkai Zasshi; 1998 May; 102(5):319-26. PubMed ID: 9619024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications.
    Ragusa M; Barbagallo C; Statello L; Caltabiano R; Russo A; Puzzo L; Avitabile T; Longo A; Toro MD; Barbagallo D; Valadi H; Di Pietro C; Purrello M; Reibaldi M
    Cancer Biol Ther; 2015; 16(9):1387-96. PubMed ID: 25951497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
    Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
    Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aqueous immune mediators in malignant uveal melanomas in comparison to benign pigmented intraocular tumors.
    Usui Y; Tsubota K; Agawa T; Ueda S; Umazume K; Okunuki Y; Kezuka T; Yamakawa N; Goto H
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):393-399. PubMed ID: 27878431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of melanin-related metabolites as markers of melanoma progression.
    Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
    Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
    Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
    J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
    Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
    Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
    Horikoshi T; Ito S
    J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The quantitative determination of 5-S-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high-pressure liquid chromatography.
    Hansson C; Edholm LE; Agrup G; Rorsman H; Rosengren AM; Rosengren E
    Clin Chim Acta; 1978 Sep; 88(3):419-27. PubMed ID: 699334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.
    Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M
    Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local environmental influences on uveal melanoma: vitreous humor promotes uveal melanoma invasion, whereas the aqueous can be inhibitory.
    Canovas D; Rennie IG; Nichols CE; Sisley K
    Cancer; 2008 Apr; 112(8):1787-94. PubMed ID: 18300240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas].
    Schaller UC; Mueller AJ; Bosserhoff AK; Haraida S; Löhrs U; Buettner R; Kampik A
    Ophthalmologe; 2000 Jun; 97(6):429-32. PubMed ID: 10916387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraocular activation of angiogenic and inflammatory pathways in uveal melanoma.
    Dunavoelgyi R; Funk M; Sacu S; Georgopoulos M; Zlabinger G; Zehetmayer M; Schmidt-Erfurth U
    Retina; 2012 Jul; 32(7):1373-84. PubMed ID: 22418780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window.
    Boyd SR; Tan D; Bunce C; Gittos A; Neale MH; Hungerford JL; Charnock-Jones S; Cree IA
    Br J Ophthalmol; 2002 Apr; 86(4):448-52. PubMed ID: 11914216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aqueous Humor Biomarkers Identify Three Prognostic Groups in Uveal Melanoma.
    Wierenga APA; Cao J; Mouthaan H; van Weeghel C; Verdijk RM; van Duinen SG; Kroes WGM; Dogrusöz M; Marinkovic M; van der Burg SSH; Luyten GPM; Jager MJ
    Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4740-4747. PubMed ID: 31731294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
    Sameshima T; Morishima T
    Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression.
    Hirai S; Kageshita T; Kimura T; Tsujisaki M; Imai K; Wakamatsu K; Ito S; Ono T
    Melanoma Res; 1997 Feb; 7(1):58-62. PubMed ID: 9067966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
    Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
    Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
    Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
    Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.